Aristeia Capital’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Aristeia Capital’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-833,510	Closed	-$738K	–	719
2022 Q1	$738K	Sell	833,510 -579,379	-41%	-$645K	0.01%	387
2021 Q4	$3.15M	Buy	1,412,889 +968,180	+218%	+$3.13M	0.05%	328
2021 Q3	$1.51M	Buy	+444,709	New	+$1.58M	0.03%	337

Other funds holding DNA.WS

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DPCM

Darlington Partners Capital Management Greenbrae, California $2.23B AUM 16.2% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

JFGLC

Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Aristeia Capital's DNA.WS Position: Q2 2022 in Review

Aristeia Capital sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q2 2022, closing a stake of 833,510 shares — an estimated $738K sold.

Aristeia Capital first reported a position in DNA.WS in Q3 2021 and held it in 3 quarters. The position peaked at $3.15M in Q4 2021. 49 funds tracked by Wall St. Rank hold DNA.WS as of Q2 2022.

Aristeia Capital reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q2 2022 after selling out during the quarter.
Aristeia Capital sold 833,510 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q2 2022, an estimated $738K.
Aristeia Capital first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 3 quarters.
Aristeia Capital's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $3.15M in Q4 2021.
49 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q2 2022.

Based on Aristeia Capital's 13F filing for Q2 2022, filed 16 Aug 2022.